All In Biotech

Drug Trial Radar · NCT07486713

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

A Multi-Center, Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of Olutasidenib on the Pharmacokinetics of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Substrates in Patients With IDH1 Mutation-Positive Malignancies Being Treated With Olutasidenib

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Feb 23, 2026

Primary completion

Apr 30, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Rigel PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Mar 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.

Conditions

  • AML (Acute Myeloid Leukemia)
  • Glioma
  • Cholangiocarcinoma
  • Solid Tumor Malignancies

Interventions

  • OlutasidenibDrug

    Participants will receive repeated dosing of olutasidenib from Day 5 to Day 22 until steady state, with an option to continue treatment up to Day 64

  • CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe SubstratesDrug

    Participants will receive a single dose of each probe substrate on Day 1 and Day 18.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Plasma Concentration-Time Curve (AUC) of Probe DrugsTime frame: Up to 96 hours after each probe drug administration.
  2. Maximum Plasma Concentration (Cmax) of Probe DrugsTime frame: Up to 96 hours after each probe drug administration.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • UCI Irvine Health

    Orange, California · Recruiting

  • New York Presbyterian Hospital-Columbia University Medical Center

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.